HMP Global’s 2026 OLN Great Debates Examines the Most Contested Questions in Solid Tumor Oncology
Each Great Debates meeting will feature clinical debate, case-based controversies, and interactive audience Q&A, so attendees can experience how experts weigh competing data in real time.
Genitourinary cancers focus expands the educational program, joining GI, lung, breast, and gynecological oncology; 2026 events held in Miami and New York City.
MALVERN, PA, UNITED STATES, February 10, 2026 /EINPresswire.com/ -- When new approvals and trial readouts change the solid tumor landscape, oncology clinicians are often left navigating areas of uncertainty in cancer care where evidence may not point to one clear choice. HMP Global’s 2026 OLN Great Debates in Solid Tumors — March 14–15 in Miami and September 26–27 in New York City — will feature expert-led discussions that help clinicians apply this emerging data into real-world clinical decision making.
Joining gastrointestinal, lung, breast, and gynecological oncology this year is a genitourinary cancers focus, reflecting the rapid expansion of biomarkers and treatment options in this disease area. Each Great Debates meeting will feature clinical debate, case-based controversies, and interactive audience Q&A, so attendees can experience how experts weigh competing data in real time and understand how those discussions inform clinical judgment.
What Is OLN Great Debates in Solid Tumors?
OLN Great Debates in Solid Tumors is designed around discussion-driven debates that test evidence in real time. Clinicians can move between concurrent debates spanning gastrointestinal, lung, breast, gynecologic, and genitourinary cancers based on what is most relevant to their practice.
The meeting is structured to help clinicians make better-informed treatment decisions when guidelines alone are not sufficient. Faculty experts challenge what the latest studies mean for patient care, clarify where evidence is strong, and highlight where uncertainty continues to shape treatment sequencing challenges.
Key benefits include:
- Practical frameworks for evidence interpretation in situations with conflicting or incomplete data
- Insight into treatment sequencing and patient selection choices that arise in everyday oncology care
- Direct exposure to how experts apply evolving evidence in practice
- Time-efficient access to a broad solid tumor curriculum across multiple focus areas in one meeting
Educational Focus Areas
The 2026 agenda covers five clinical focus areas: gastrointestinal, lung, breast, gynecologic, and — new for 2026 — genitourinary cancers led by Matthew Galsky, MD, Professor of Medicine (Hematology and Medical Oncology) and Director of Genitourinary Medical Oncology at The Tisch Cancer Institute.
“In genitourinary oncology, there are many moments where multiple options are reasonable, and the real question is how to interpret the evidence for the patient in front of you,” Galsky said. “The format at OLN Great Debates in Solid Tumors helps clinicians leave with sharper reasoning they can apply immediately in practice.”
Featured Sessions
- Biomarkers Beyond Boundaries: Advancing Precision Oncology with Tumor-Agnostic Therapies
- Radiopharmaceuticals in Solid Tumors: What Every Oncologist Should Know
- Should We Order ctDNA in the Adjuvant Setting for Early-Stage Breast Cancer Outside of Clinical Trials?
- Are RAS Inhibitors Ready for Prime-Time Use as a Standard of Care in Pancreatic Cancer?
- Resectable Lung Cancer: Neoadjuvant Only vs Perioperative Therapy
Who Should Attend
OLN Great Debates in Solid Tumors is intended for oncology healthcare professionals involved in the care of patients with solid tumors. The meeting is relevant for clinicians engaged in treatment decision making, including physicians, oncology nurses, advanced practice providers, pharmacists, fellows, residents, and other members of the care team.
Event Details
- Event: 2026 OLN Great Debates in Solid Tumors
- Dates and Locations: March 14–15 | Miami; September 26–27 | New York City
- Website
- Registration
About HMP Global
HMP Global is the omnichannel market leader in healthcare events, education, and insight — with a mission to improve patient care. For 40 years, the company has built trusted brands including Psych Congress, the premier source for mental health education, and the Symposium on Advanced Wound Care (SAWC), the largest wound care meeting in the world. HMP Global partners with leading experts around the world to deliver more than 450 annual events, medical strategy, and marketing for pharmaceutical and medical device customers through HMP Collective, and pharmaceutical market insight, engaging a global community of healthcare stakeholders that includes nearly 2 million clinicians across 600 medical specialties as well as managed care, behavioral health, senior living, emergency medical, and pharmaceutical commercialization professionals. For more information, follow HMP Global on LinkedIn or visit hmpglobal.com.
Sandi Beason, APR
HMP Global
pr@hmpglobal.com
Visit us on social media:
LinkedIn
Facebook
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
